<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00175994</url>
  </required_header>
  <id_info>
    <org_study_id>2005-001649-41</org_study_id>
    <secondary_id>K117</secondary_id>
    <nct_id>NCT00175994</nct_id>
  </id_info>
  <brief_title>Bioavailability and Metabolism of Voriconazole in Relation to Its Modulation by the CYP2C19 Genetic Polymorphism</brief_title>
  <official_title>Bioavailability and Metabolism of Voriconazole as a Function of the CYP2C19 Genotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <brief_summary>
    <textblock>
      The purposes of this study are:&#xD;
&#xD;
        -  To determine the absolute bioavailability of voriconazole after a single oral dose (400&#xD;
           mg voriconazole [VFEND brand]) in comparison to intravenous (i.v.) administration (400&#xD;
           mg VFEND, equivalent to two 10 mg/ml-infusates, each containing 200 mg voriconazole&#xD;
           [VRC]) in healthy individuals stratified according to the three predominant CYP2C19&#xD;
           genotypes&#xD;
&#xD;
        -  To investigate the possible pathways of metabolism and their modulation according to&#xD;
           genetic polymorphism of CYP2C19 after i.v. and oral administration of VRC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As CYPs are mainly involved in VRC metabolism it is likely that also gut wall metabolism by&#xD;
      CYPs occurs. However, no substantial first pass metabolism of VRC has been reported. In&#xD;
      humans the VRC metabolism has not been studied systematically. It is therefore important to&#xD;
      assess VRC metabolism on its own and in addition the influence of CYP2C19 genetic&#xD;
      polymorphisms on the formation of the different VRC metabolites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>Healthy</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good state of health (physically and mentally)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any regular drug treatment within the last two months except for oral contraceptives&#xD;
             in female participants&#xD;
&#xD;
          -  Any intake of a substance known to induce or inhibit drug metabolising enzymes or&#xD;
             transport system enzymes within a period of less than 10 times the respective&#xD;
             elimination half-life&#xD;
&#xD;
          -  Any acute or chronic illness or clinically relevant findings in the pre-study&#xD;
             examination&#xD;
&#xD;
          -  Allergies (except for mild forms of hay fever) or history of hypersensitivity&#xD;
             reactions&#xD;
&#xD;
          -  Smoking (regular or irregular)&#xD;
&#xD;
          -  Excessive alcohol drinking (more than approximately 30 g alcohol per day)&#xD;
&#xD;
          -  Positive drug screening or known or admitted drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerd Mikus, MD BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department Internal Medicine VI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Unit, Department Internal Medicine VI</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>April 16, 2007</last_update_submitted>
  <last_update_submitted_qc>April 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2007</last_update_posted>
  <keyword>voriconazole</keyword>
  <keyword>genotype</keyword>
  <keyword>bioavailability</keyword>
  <keyword>metabolic clearance</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

